RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Rutherrinfredgoodwinson wrote: No intention to impugn fellow posters OM many if not most of whom have far greater knowledge/expertise in this area than I do - and that includes you!
Continue to doubt though whether unquestioning patience is any sort of virtue in the world of small biotech where value can (and quite suddenly) be diminished or even destroyed by the progress of others?
This from today’s press:
https://www.dailymail.co.uk/health/article-10724471/Experts-hail-new-double-drug-therapy-boost-survival-lung-cancer-patients.html
Hi Fred...
This stressful world of small biotech investing is certainly not for the faint of heart or impatient. There's always that painful paradox awaiting when I try to rationally base my patience on data/logic...yet without a healthy dose of patience, one will inevitably lack the necessary data/logic. The pain only heightens when data trends take forever and a day to establish themselves...& sometimes requiring a PhD in statistics to interpret ; ). Fortunately, we have esteemed/experienced scientists on our TLT team (i.e. Dr. Mandel M.D., PhD & Dr. Madzarevic PhD) & several knowledgeable posters who are able to cut to the chase re: the significance of the current data. And based on all of the studies to date, it's hard to argue the validity of this science imo.
That new double-drug approach you referenced looks promising, but the reported 37% reduction in disease recurrence certainly isn't the cure-all for lung cancer & will more than likely be improved upon in the near future imo. There was another recent study that demonstrated significant synergy/efficacy when using a combination of a Ruthenium complex & a chemo drug against breast cancer cells preclinically. The many promising studies of Ruthenium complexes & other biosimilars indicate great potential for their additional use as a combination drug or adjuvant. All imo. Good luck...